<DOC>
	<DOCNO>NCT02281409</DOCNO>
	<brief_summary>The purpose study find effect , good and/or bad , KW-0761 , investigational drug , patient cancer .</brief_summary>
	<brief_title>Safety , Tolerability , Immunoregulatory Activity Mogamulizumab ( KW-0761 ) Subjects With Advanced and/or Metastatic Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Informed Consent form sign subject . Males females 18 year old time dose initiation . Histologically confirm unresectable solid tumor malignancy least 1 measurable lesion . In expansion phase , eligibility limit metastatic triple negative breast cancer receive prior taxane anthracycline therapy ; Metastatic NSCLC ALK+ EGFR sensitize mutation ; metastatic gastric cancer Previously treat advanced cancer curative therapy option available Karnofsky Performance Status ≥70 30 day baseline period immediately prior dosing . Evidence adequate organ function standard laboratory test : Serum creatinine ( Cr ) ≤1.5 X upper limit normal ( ULN ) Serum total ( T Bil ) ≤1.5 X ULN ( prior diagnosis past history consistent Gilbert 's syndrome exception ) Serum aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≤2.5 X ULN Platelets ( Plts ) ≥ 100,000/μl Hemoglobin ( Hgb ) ≥ 9.0 g/dL Absolute neutrophil count ( ANC ) ≥1000/mm3 All female subject childbearing age must either surgically sterile , postmenopausal least 1 year , use acceptable method contraception . Examples adequate method contraception include abstinence , intrauterine device , hormonal contraception , use spermicide condom sexual partner , partner vasectomy . Adequate contraception must use begin screen period least 16 week last dose KW0761 . Male subject partner childbearing potential must use barrier method contraception day first dose KW0761 least 16 week last dose . Life expectancy &gt; 12 week Previously treat advanced cancer additional therapy option available know prolong survival . Evidence clinically significant central nervous system ( CNS ) metastases symptomatic CNS metastasis within 30 day prior dose . History autoimmune disease , except vitiligo , diabetes , autoimmune thyroiditis . A history major surgery within 6 week prior dose . Any history systemic anticancer therapy ( standard experimental ) complete within 30 day prior dose , exception palliative ablation lesion ( ) long measurable disease lesion ( ) remain evaluation exploratory endpoint . Any concomitant serious physical illness cancer ( i.e. , immune deficiency disease , bleed disorder , etc . ) within 1 year prior dose . Any history StevensJohnson syndrome . Clinically significant heart disease , define NYHA Class III IV . Any allergic reaction previously administer monoclonal antibody therapeutic protein . Any significant systemic infection within 4 week prior dose . Pregnancy breastfeed . An exist diagnosis HIV , hepatitis B , hepatitis C , current laboratory finding clinical sign symptom suggest condition . Subjects active herpes simplex herpes zoster . Subjects history herpes zoster outbreak within last year also exclude . Subjects prophylaxis herpes start take medication least 30 day prior study entry , continue take prescribed medication duration study . Unresolved immune related adverse event follow prior biological therapy Use investigational drug within 30 day prior dose . Any condition require likely require treatment systemic corticosteroid within Core Study Period short term followup . Subjects myocardial infarction within last 6 month . Subjects immunomodulatory drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Mogamulizumab ( KW-0761 )</keyword>
	<keyword>14-135</keyword>
</DOC>